NPCE Stock Analysis: Buy, Sell, or Hold?
NPCE - Neuropace, Inc. Common Stock
$12.89
-0.86 (-6.25%)
▼
5d:
-12.96%
30d:
-18.26%
90d:
-23.55%
WAIT
LOW Confidence
Analysis Updated: Jul 31, 2026 12:00 AM ET
Earnings: Aug 11, 2026
7d
Get Alerted When NPCE Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: NPCE is down 13.0% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: NPCE is down 13.0% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: NPCE is currently trading at $12.89, which is considered oversold relative to its 30-day fair value range of $14.63 to $16.98.
Technical Outlook: Technically, NPCE is in a uptrend. The price is currently testing key support at $12.66. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 6.3% recently.
Market Sentiment: NPCE has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Implied Volatility is high (95th percentile), indicating expensive options premiums. This environment often favors selling options or covered calls to generate income. Wall Street analysts see significant upside, with an average price target of $20.22 (+56.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, NPCE is in a uptrend. The price is currently testing key support at $12.66. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 6.3% recently.
Market Sentiment: NPCE has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Implied Volatility is high (95th percentile), indicating expensive options premiums. This environment often favors selling options or covered calls to generate income. Wall Street analysts see significant upside, with an average price target of $20.22 (+56.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$14.63 -
$16.98
Company Quality Score
50/100
(HOLD)
Options IV Signal
95th percentile
(EVENT RISK)
Volume Confirmation
HIGH
Confidence Score
41.7%
Protect Your Profits
Holding NPCE? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Options expensive (IV 95th percentile)
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-6.3%)
- BULLISH: Trading 56.9% below Wall St target ($20.22)
Trading Range Analysis
30-Day Trading Range
$14.63 -
$16.98
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$2.92
(22.6%)
Support & Resistance Levels
Support Level
$12.66
Resistance Level
$16.35
Current Trend
Uptrend
Technical data as of
Jul 31, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-43.87
Wall Street Target
$20.22
(+56.9%)
Revenue Growth (YoY)
-2.0%
Profit Margin
-21.7%
Share & Embed Analysis
Last updated: August 03, 2026 12:43 AM ET
Data refreshes hourly during market hours. Next update: 1:43 AM
Data refreshes hourly during market hours. Next update: 1:43 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NPCE showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
DXCM
DexCom Inc |
STRONG BUY
27 analysts |
$93 | 49 HOLD |
|
SYK
Stryker Corporation |
BUY
32 analysts |
$384 | 51 HOLD |
|
ABT
Abbott Laboratories |
STRONG BUY
27 analysts |
$118 | 52 HOLD |
|
MDT
Medtronic PLC |
BUY
32 analysts |
$98 | 57 HOLD |
|
EW
Edwards Lifesciences Corp |
HOLD
32 analysts |
$101 | 52 HOLD |
Advanced NPCE Option Strategies
Professional options setups generated by AI based on today's NPCE price and gamma walls.
